Combatting the Energy Crisis: Eworld Showcases Low-Energy Glass Processing Machinery and Sustainable Solutions at Major Global Expos
International trade shows highlight Eworld's energy-efficient glass processing technologies for architectural and industrial applications JINAN, China, Jan. 27, 2026 /PRNewswire/ -- High energy costs and tightening environmental regulations are no...
Tineco Elevates Modern Living With a Smarter, More Balanced Floor Care Portfolio
SEATTLE, Jan. 27, 2026 /PRNewswire/ -- As modern homes continue to evolve, consumers are increasingly seeking appliances that combine performance, thoughtful design, and long-term value. Tineco, a leader in intelligent floor care solutions, brings...
Beetles Gel Polish Celebrates 5-Star Women's Basketball Recruit Jerzy Robinson's College Commitment
Top ranked women's basketball recruit Jerzy Robinson marks a defining life chapter through self-expression with Beetles Gel Polish. NEW YORK, Jan. 27, 2026 /PRNewswire/ -- As young athletes navigate high-pressure moments both on and off the court,...
Home Control Signs Memorandum of Understanding with NTU Singapore to Explore AIoT Home Healthcare Ecosystem
HONG KONG, Jan. 27, 2026 /PRNewswire/ -- Home Control International Limited ("Home Control" or the "Company", together with its subsidiaries, the "Group"; Stock Code: 1747.HK) is pleased to announce that it has entered into a Strategic Memorandum of...
AGCO Foundation Partners with the University of Sydney to Boost Resilience in Rural Communities
The AU$150,000 partnership will create a dedicated agriculture program for the university. DULUTH, Ga., Jan. 28, 2026 /PRNewswire/ -- AGCO Foundation, a private foundation working to transform lives in farming communities, announced a new...
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural history expected worsening of cUHDRS in symptomatic patients of -0.73 points over nine months, based...
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV),...
RegASK Achieves ISO 27701 Privacy Certification, Strengthening Verifiable Trust in the AI Era
Agentic AI regulatory intelligence leader strengthens its enterprise privacy and governance framework. NEW YORK and SINGAPORE, Jan. 27, 2026 /PRNewswire/ -- As enterprises increasingly rely on AI to navigate the complex global regulatory landscape,...